refractory multiple myeloma
Showing 1 - 25 of 105
Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma Trial in Boston (Elranatamab)
Not yet recruiting
- Refractory Multiple Myeloma
- +2 more
-
Boston, Massachusetts
- +2 more
Nov 17, 2023
Recurrent Multiple Myeloma, Refractory Multiple Myeloma Trial in Columbus (procedure, drug, biological)
Not yet recruiting
- Recurrent Multiple Myeloma
- Refractory Multiple Myeloma
- Biospecimen Collection
- +9 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Aug 1, 2023
Recurrent Multiple Myeloma, Refractory Multiple Myeloma Trial in Los Angeles (procedure, drug, other)
Not yet recruiting
- Recurrent Multiple Myeloma
- Refractory Multiple Myeloma
- Bone Marrow Aspiration
- +10 more
-
Los Angeles, CaliforniaMelanie Ayala Ceja
Jul 10, 2023
Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma Trial in Boston (Isatuximab, Belantamab mafodotin, Pomalidomide)
Not yet recruiting
- Relapsed Cancer
- +2 more
- Isatuximab
- +3 more
-
Boston, Massachusetts
- +1 more
Jun 19, 2023
Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in Miami (Iberdomide, Carfilzomib, Daratumumab)
Not yet recruiting
- Refractory Multiple Myeloma
- Relapsed Multiple Myeloma
- Iberdomide
- +6 more
-
Miami, FloridaUniversity of Miami
May 31, 2023
Learn How Triple Class Refractory Multiple Myeloma Are Treated
Not yet recruiting
- Relapse Multiple Myeloma
- Refractory Multiple Myeloma
- (no location specified)
Feb 15, 2023
Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,
Recruiting
- Refractory Multiple Myeloma
- Relapsed Multiple Myeloma
- Manufactured Anti-BCMA CAR-T cells
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jan 6, 2023
Multiple Myeloma, Refractory Multiple Myeloma Trial (procedure, drug, radiation)
Withdrawn
- Multiple Myeloma
- Refractory Multiple Myeloma
- nonmyeloablative allogeneic hematopoietic stem cell transplantation
- +7 more
- (no location specified)
Jan 4, 2023
Multiple Myeloma in Relapse, Refractory Multiple Myeloma Trial in China, Taiwan (TJ202 and Dexamethasone)
Active, not recruiting
- Multiple Myeloma in Relapse
- Refractory Multiple Myeloma
- TJ202 and Dexamethasone
-
Beijing, Beijing, China
- +17 more
Oct 17, 2022
Multiple Myeloma in Relapse, Refractory Multiple Myeloma Trial in China, Taiwan (TJ202, Lenalidomide and Dexamethasone,
Active, not recruiting
- Multiple Myeloma in Relapse
- Refractory Multiple Myeloma
- TJ202, Lenalidomide and Dexamethasone
- Lenalidomide and Dexamethasone
-
Beijing, Beijing, China
- +40 more
Oct 17, 2022
Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial in Worldwide (Dexamethasone, Daratumumab, Carfilzomib)
Completed
- Relapsed Multiple Myeloma
- Refractory Multiple Myeloma
- Dexamethasone
- +2 more
-
Boca Raton, Florida
- +112 more
Sep 9, 2022
Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial in United States (REGN5459)
Active, not recruiting
- Relapsed Multiple Myeloma
- Refractory Multiple Myeloma
-
Indianapolis, Indiana
- +6 more
Aug 16, 2022
Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in Milwaukee (Belantamab mafodotin)
Recruiting
- Refractory Multiple Myeloma
- Relapse Multiple Myeloma
- Belantamab mafodotin
-
Milwaukee, WisconsinFroedtert & the Medical College of Wisconsin
Aug 3, 2022
Multiple Myeloma in Relapse, Refractory Multiple Myeloma Trial in Israel (ixazomib-pomalidomide-dexamethasone)
Recruiting
- Multiple Myeloma in Relapse
- Refractory Multiple Myeloma
-
Afula, Israel
- +7 more
Jul 10, 2022
Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial (Rapid Infusion Isatuximab)
Withdrawn
- Relapsed Multiple Myeloma
- Refractory Multiple Myeloma
- Rapid Infusion Isatuximab
- (no location specified)
Jul 3, 2022
Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in New York (MCARH125, MCARH109)
Recruiting
- Multiple Myeloma
- +2 more
- MCARH125
- MCARH109
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jun 20, 2022
Relapse Multiple Myeloma, Refractory Multiple Myeloma Trial in Hangzhou (BCMA Targeted CAR T-cells)
Recruiting
- Relapse Multiple Myeloma
- Refractory Multiple Myeloma
- BCMA Targeted CAR T-cells
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, Medical College, Zhejiang Univers
Jun 18, 2022
Multiple Myeloma, Refractory Multiple Myeloma Trial in Houston (Digital Health Coaching Program, Fitbit)
Recruiting
- Multiple Myeloma
- Refractory Multiple Myeloma
- Digital Health Coaching Program
- Fitbit
-
Houston, TexasThe University of Texas MD Anderson Cancer Center
Jun 17, 2022
Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in New York (Daratumumab, Clarithromycin,
Recruiting
- Multiple Myeloma
- +2 more
- Daratumumab
- +3 more
-
New York, New YorkWeill Cornell Medicine - Multiple Myeloma Center
Jun 8, 2022
Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial (Elotuzumab, Selinexor, and Dexamethasone (ESd))
Withdrawn
- Relapsed Multiple Myeloma
- Refractory Multiple Myeloma
- Elotuzumab, Selinexor, and Dexamethasone (ESd)
- (no location specified)
Apr 27, 2022